Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 studyMilind Javle, Ghassan K. Abou‐Alfa, Sameek Roychowdhury et al.|The Lancet. Gastroenterology & hepatology|2021Cited by 423
Direct Measurement of ATP7B Peptides Is Highly Effective in the Diagnosis of Wilson DiseaseChristopher J. Collins, Si Houn Hahn, Han‐Wook Yoo et al.|Gastroenterology|2021Cited by 82
Experience on switching trientine formulations in Wilson disease: Efficacy and safety after initiation of TETA 4HCl as substitute for TETA 2HClIsabelle Mohr, Karl Heinz Weiss, Hélène Bourhis et al.|Journal of Gastroenterology and Hepatology|2022Cited by 10
Résultats à un an de l’étude chelate : comparaison de la trientine tétrahydrochloride à la D-Pénicillamine chez des patients stables atteints de la maladie de WilsonAurélia Poujois, Michael L. Schilsky, Zuin Massimo Giovanni et al.|Revue Neurologique|2022Cited by 0
Évolution des symptômes neurologiques dans la maladie de Wilson après un an de traitement par dichlorhydrate de trientine : avantage aux femmes !Aurélia Poujois, Carlot Kruse, Mickaël Alexandre Obadia et al.|Revue Neurologique|2022Cited by 0